Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

CzechiaBack to Czechia

Clinical trials in Ostrava – page 36

557 clinical trials in Ostrava, Czechia across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Ostrava at a glance
557
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

557 trials in Ostrava

Open in trial search

Chronic graft versus host disease

Not recruiting

Study of Belumosudil and Prednisone for Patients Aged 12 and Older with Newly Diagnosed Chronic Graft Versus Host Disease

Registered drug
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Plasma cell myeloma

Not recruiting

Study Comparing Talquetamab, Pomalidomide, and Teclistamab for Patients with Relapsed or Refractory Myeloma After 1 to 4 Prior Treatments

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Plasma cell myeloma

Not recruiting

Study of Isatuximab, Lenalidomide, and Dexamethasone for Patients with High-Risk Smoldering Multiple Myeloma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Hypertension

Not recruiting

Study on Baxdrostat for Reducing Blood Pressure in Patients with Uncontrolled or Resistant Hypertension

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Follicular lymphoma

Not recruiting

Study of Ibrutinib and Rituximab for Patients with Follicular Lymphoma

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Gastric cancer

Not recruiting

Study of Bemarituzumab with Chemotherapy and Nivolumab in Untreated Advanced Gastric and Gastroesophageal Junction Cancer Patients with FGFR2b Overexpression

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Chronic lymphocytic leukaemia

Not recruiting

Study on the Use of Human Normal Immunoglobulin for Preventing Infections in Patients with Chronic Lymphocytic Leukemia and Secondary Immunodeficiency

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Octapharma Pharmazeutika Produktionsgesellschaft mbH

Endometrial cancer

Not recruiting

Study on MK-2870 for Patients with Endometrial Cancer After Platinum and Immunotherapy Treatment

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer metastatic+2

Not recruiting

Study on Trastuzumab Emtansine, Pertuzumab, and Atezolizumab for Patients with HER2-Positive Metastatic Cancer Who Benefited from Previous Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Plasma cell myeloma

Not recruiting

Study of Daratumumab with Drug Combination for Patients with Newly Diagnosed Multiple Myeloma Eligible for High-Dose Therapy

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Prostate cancer metastatic

Not recruiting

Study of Apalutamide and Androgen Deprivation Therapy for Patients with Metastatic Hormone-sensitive Prostate Cancer

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Janssen Cilag International

Chronic lymphocytic leukaemia

Not recruiting

Study Comparing Sonrotoclax and Zanubrutinib with Venetoclax and Obinutuzumab for Patients with Untreated Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:BeOne Medicines AG

Other cities in Czechia

The busiest research cities in the country

All 150 cities in Czechia

Clinical research in Ostrava

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on metastatic prostate cancer and lung cancer treatments. Studies include evaluation of novel therapies for multiple myeloma and various forms of leukemia.

  • Prostate Cancer Treatment Advances
  • Small Cell Lung Cancer Therapy
  • Blood Cancer Interventions

Multiple collaborative studies exploring targeted therapies and combination treatments for advanced-stage cancers.

02 Immunology and Inflammatory Diseases

Research targeting inflammatory bowel diseases, including studies on Crohn's Disease and ulcerative colitis. Investigations into novel treatments for psoriatic arthritis.

  • Inflammatory Bowel Disease Management
  • Autoimmune Conditions
  • Chronic Inflammatory Disorders

Comprehensive evaluation of innovative therapeutic approaches for chronic inflammatory conditions.

03 Cardiovascular and Infectious Diseases

Studies examining cardiovascular disease treatments and prevention strategies. Research on bacterial infections and antimicrobial therapies, including trials for complicated urinary tract infections.

  • Heart Disease Prevention
  • Infection Management
  • Antibiotic Optimization

Advanced research combining preventive approaches with targeted therapeutic interventions.

Back to CzechiaAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.